Cristian Rivera Foundation Committee Member Darlene Rodriguez sat down with Cristian Rivera Foundation founder John “Gungie” Rivera and Dr. Mark Souweidane of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College to learn more about DIPG and the Cristian Rivera Foundation’s amazing efforts to fund research into its cure. The segment aired on Monday September 30, the same day that Rodriguez hosted the Fifth Annual Cristian Rivera Foundation Gala. To see the full segment, visit http://www.nbcnewyork.com/video/#!/on-air/as-seen-on/The-Cristian-Rivera-Foundation/225787111.
The Cristian Rivera Foundation is pleased to announce that Dr. Mark Souweidane, leading pioneer of the DIPG clinical trials at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, has just operated on the trial’s second patient today, Tuesday, July 17th! This clinical trial has been making great strides in the battle against DIPG, providing hope for families who previously had none. Dr. Souweidane operated on the first patient of the trial on Monday, May 1st and the beautiful 4-year-old girl has been doing surprisingly well. We are so proud to have helped fund this groundbreaking clinical trial, one that we hope will lead to finding a cure for DIPG. Currently, DIPG is an incurable disease which claims the lives of 200-300 children between the ages of 1 and 9 in the United States each year, a statistic we hope to abolish in the future. Full Steam Ahead!
Cristian Rivera Foundation Committee Member Solange Osorio and John “Gungie” Rivera paid a visit to Dr. Mark Souweidane at Weill Cornell Medical Center on Wednesday January 26th to personally bring him a $10,000 check from the Foundation. Thus far the Cristian Rivera Foundation has donated $40,000 to Dr Souweidane’s research. The money will help pay for Dr. Souweidane’s clinical trials, which aim to bypass the blood-brain barrier and deliver treatment directly to the Pontine Glioma tumor. While they were there, they got the latest update on Dr. Souweidane’s research. The trials are set to begin in the next few months, after they’ve finished raising money and get final approval.